B7-CD28 Family——PD-1/PD-L1/PD-L2 Pathway

The PD-1/PD-L1/PD-L2 pathway is a key "brake" mechanism in the immune system. In the field of cancer therapy, inhibitors targeting this pathway have become revolutionary treatments. Through their interactions, this pathway inhibits the activation, proliferation, and effector functions of T cells, thereby maintaining self-immunotolerance under physiological conditions. However, in the tumor microenvironment, it is exploited by tumors to achieve immune escape.
As a "cornerstone track" in cancer immunotherapy, the PD-(L)1 field has undergone over a decade of development since the first drug was approved, yet it remains highly active. To improve efficacy and overcome resistance, combination therapies (such as in combination with chemotherapy and anti-angiogenic drugs) and novel drugs like bispecific antibodies have become important R&D directions.

>>>Immune Checkpoint Bispecific Antibody Targets

The PD-1/PD-L1 Axis and Co-signaling Networks: Orchestrating T Cell Responses in Cancer and Autoimmunity

The PD-1/PD-L1 Axis and Co-signaling Networks: Orchestrating T Cell Responses in Cancer and Autoimmunity
Resource:https://www.globecancer.com/azzx/show.php?itemid=15812

>> Scroll to view

Drug Strategy Strategy Type Representative Drugs / Regimens Core Mechanism / Objective
PD-L1-targeting ADC
ADC
1. PD-L1 ADC: Henlius HLX43
2. PD-L1/αvβ6 integrin BsADC: Alphamab JSKN022
1. Target PD-L1 and achieve targeted killing through the cytotoxic payload of ADC
2. Dual targeting of PD-L1 and αvβ6 integrin to enhance tumor targeting and killing efficacy
PD-1 Plus: BsAb
Immune Escape Inhibition + Anti-angiogenesis
PD-1/VEGF BsAb: Akeso Ivonescimab (AK112)
Simultaneously block PD-1-mediated immune escape signals, inhibit VEGF-mediated tumor angiogenesis, improve the tumor microenvironment, and enhance immunotherapeutic efficacy.
Immune Escape Inhibition + Immune Agonism
1. PD-1/IL-2 BsAb: InnoCare IBI363
2. PD-L1/4-1BB BsAb: ImmuneOnco LBL-024
While blocking immune escape, activate immune effector cells such as T cells through the IL-2/4-1BB pathway to overcome immunotherapy resistance.
Multiple Immune Escape Inhibition
1. PD-1/TIGITBsAb: AstraZeneca Rivegostomig
2. PD-1/CTLA-4BsAb: Akeso Cadonilimab
Simultaneously block multiple immune checkpoint pathways including PD-1, TIGIT, and CTLA-4 to strengthen the inhibition of immune escape.
Combination of PD-1/PD-L1 Inhibitor and ADC
Combination Therapy
PD-1 Inhibitor Keytruda + Nectin-4 ADC Padcev
Leverage the targeted killing effect of ADC and the immune activation function of PD-1/PD-L1 inhibitor to achieve synergistic antitumor effect and improve treatment response.
To meet your R&D needs for drugs targeting the PD-(L)1/PD-L2 pathway, ACROBiosystems has specifically developed a series of products covering the entire R&D pipeline. These include highly active PD-1/PD-L1/PD-L2 target proteins, PD-1/PD-L1 functional cell lines, and inhibitor screening kits, catering to the entire process from basic mechanism research to preclinical drug evaluation and production quality control.
Furthermore, addressing potential unconventional needs in R&D, we also offer customized services: such as specific species/mutant protein customization, exclusive functional cell model construction, and experimental protocol optimization guidance. This aims to accelerate your R&D process for drugs related to the PD-1/PD-L1/PD-L2 pathway, enhancing drug screening efficiency and clinical translation success rates.

Product Features

Protein
High purity verified by MALS/HPLC.
Multiple species, tags, labels.
High bioactivity verified by ELISA/SPR/FACS.
Stringent QC ensures high batch-to-batch consistency.
Functional Cell Lines
Developed based on mature cell construction platforms, strictly screened and validated.
Stable passage >20 generations, ensuring reliable experimental results.
Original cell lines obtained with legal commercial licenses, global commercial authorization support available.
Inhibitor Screening Kits
Two technical routes: Competitive ELISA and TR-FRET
TR-FRET-based: Wash-free; High-throughput (supports 500 tests); Comprehensive verification data
Competitive ELISA-based: Accurate and reliable; High reproducibility; 96T & fast universal; Minimal matrix interference
Pharmacokinetic (PK) Assay Kits
Low background
Universal and fast
High batch-to-batch consistency
High stability
Diversified product line

Product List

Protein
Cell Line
Inhibitor Screening ELISA
PK ADA ELISA
Cat. No.MoleculeProduct DescriptionOrder Now
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order

Validation Data

Electrophoresis (SDS-PAGE)
Electrophoresis (SDS-PAGE)

Human PD-L1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 98% (With Star Ribbon Pre-stained Protein Marker).

Protein High Purity Verified by SEC-MALS
Protein High Purity Verified by SEC-MALS

The purity of Human PD-L1, His Tag (Cat. No. PD1-H5229) is more than 90% and the molecular weight of this protein is around 30-50kDa verified by SEC-MALS.

Request Report
High Binding Activity of PD-1 to PD-L2 Verified by ELISA
High Binding Activity of PD-1 to PD-L2 Verified by ELISA

Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 2 μg/mL (100 μL/well) can bind Human PD-L2, Mouse IgG1 Fc Tag (Cat. No. PD2-H52A5) with a linear range of 10-156 ng/mL (Routinely tested).

Request Protocol

High Binding Affinity of PD-1 to PD-L1 Verified by SPR
High Binding Affinity of PD-1 to PD-L1 Verified by SPR

Human PD-1, Fc Tag (Cat. No. PD1-H5257) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 3.6 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

Request Protocol

High Binding Affinity of PD-1 to PD-L1 Verified by BLI
High Binding Affinity of PD-1 to PD-L1 Verified by BLI

Loaded Human PD-1, Fc Tag, low endotoxin (Cat. No. PD1-H5257) on Protein A Biosensor, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 5.3 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

Request Protocol

High Binding Affinity of PD-1 to PD-L1 Verified by Cellular Assay
High Binding Affinity of PD-1 to PD-L1 Verified by Cellular Assay

Immobilized cell surface PD-1 (5x104 of cells per well) can bind Human PD-L1, Fc Tag (Cat. No. PD1-H5258) with an EC50 of 0.029 μg/mL (Routinely tested).

Request Protocol

High Binding Activity of PD-L1 to PD-L1 Antibody Verified by ELISA
High Binding Activity of PD-L1 to PD-L1 Antibody Verified by ELISA

Immobilized Biotinylated Human PD-L1, Avitag,His Tag (Cat. No. PD1-H82E5) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Anti-PD-L1 MAb, Human IgG1 with a linear range of 0.2-3 ng/mL (Routinely tested).

Request Protocol

High Binding Affinity of PD-L1 to PD-L1 Antibody Verified by SPR
High Binding Affinity of PD-L1 to PD-L1 Antibody Verified by SPR

Anti-Human PD-L1 Mab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 0.286 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Request Protocol

Binding Activity to BSAb Verified by ELISA
Binding Activity to BSAb Verified by ELISA

Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 5 μg/mL, add increasing concentrations of Cadonilimab (PD-1 x CTLA-4 bispecific antibody) and then add Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.99 ng/mL (Routinely tested).

Request Protocol

Binding Activity to BSAb Verified by ELISA
Binding Activity to BSAb Verified by ELISA

Immobilized Human VEGF165, His Tag (Cat. No. VE5-H5248) at 2 μg/mL, add increasing concentrations of Ivonescimab and then add Biotinylated Human PD-1 Protein, Avitag,His Tag (Cat. No. PD1-H82E4) at 2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.17 ng/mL (Routinely tested).

Request Protocol
The binding activity between PD-1 and PD-L1-overexpressing cell lines was verified by FACS.
The binding activity between PD-1 and PD-L1-overexpressing cell lines was verified by FACS.

Flow Cytometry assay shows that Human PD-1 Protein, Fc Tag (Cat. No. PD1-H5257) can bind to 293 cell overexpressing human PD-L1. The concentration of PD-1 used is 1 μg/mL (Routinely tested).

Request Protocol

The competitive inhibitory effect of PD-L1 antibodies on the binding of human PD-1/PD-L1 was verified by FACS.
The competitive inhibitory effect of PD-L1 antibodies on the binding of human PD-1/PD-L1 was verified by FACS.

FACS analysis shows that the binding of Human PD-L1, Fc Tag (Cat. No. PD1-H5258) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing Anti-PD-L1 antibody. The concentration of PD-L1 used is 10 μg/mL. The IC50 is 12.92 μg/mL (Routinely tested).

Request Protocol

Screening of PD1/PD-L1 inhibitors using the Human PD-1/PD-L1 Inhibitor Screening Kit (TR-FRET)
Screening of PD1/PD-L1 inhibitors using the Human PD-1/PD-L1 Inhibitor Screening Kit (TR-FRET)

The Human PD-1 / PD-L1 Inhibitor Screening Kit (TR-FRET) (Cat. No. FRT-P019) is suitable for the detection of PD1/PD-L1 inhibitors. It shows that both Atezolizumab, Nofazinlimab and Pembrolizumab exhibit good inhibitory activity in this TR-FRET competition assay.

Request Protocol

Detection of the inhibitory effect of anti-PD-L1 neutralizing antibodies on PD-L1: PD-1 binding using the PD-L1: PD-1 [Biotinylated] Inhibitor Screening Kit
Detection of the inhibitory effect of anti-PD-L1 neutralizing antibodies on PD-L1: PD-1 binding using the PD-L1: PD-1 [Biotinylated] Inhibitor Screening Kit

Serial dilutions of Anti-PD-L1 Neutralizing antibody (Cat. No. EP133) (1:1 serial dilution, from 2 μg/mL to 0.015625μg/mL) was added into PD-L1: Biotinylated PD-1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Request Protocol

Clinical Drug Information Table

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
68Ga-Mirc415ClinicalBeijing Cancer HospitalLung Neoplasms
Details
IMGS-001IMGS-001Phase 1 ClinicalThe University Of Texas MD Anderson Cancer CenterColorectal Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
CA-170CA-170; AUPM-170Phase 3 ClinicalAurigeneCarcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours
Details
89Zr-KN035(Wuxi No. 4 People's Hospital)ClinicalWuxi No. 4 PeopleSolid tumours
Details
CTB-1CTB-1ClinicalGTS Biotech LLCNeoplasms
Details
68Ga-WL12[68Ga]WL12; 68Ga-WL12; 68Ga-WL-12ClinicalBeijing Cancer HospitalLung Neoplasms
Details
18F-WL1218F-WL12; 18F-WL-12ClinicalBeijing Cancer HospitalLung Neoplasms
Details
[68Ga]Ga-NOTA-RW102ClinicalHuashan HospitalCarcinoma, Non-Small-Cell Lung
Details
68Ga-THP-APN09ClinicalBeijing Cancer HospitalLung Neoplasms
Details
18F-BMS-986192BMS-986192-[18F]ClinicalBristol-Myers Squibb CompanyNeoplasms
Details
Durvalumab/Selumetinib sulfatePhase 1 ClinicalAstrazeneca PlcNeoplasms
Details
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu)Phase 1 ClinicalJiangsu Huaiyu Pharmaceutical Co LtdSolid tumours
Details
GarivulimabBGB-A333Phase 1 ClinicalBeOne Medicines LtdNeoplasms; Solid tumours
Details
BJ-005BJ-005Phase 1 ClinicalBoji Biomedical Technology (Hangzhou) Co LtdLymphoma; Solid tumours
Details
IBI-323(Innovent Biologics)IBI-323Phase 1 ClinicalNeoplasms; Solid tumours
Details
GNC-039GNC-039Phase 1 ClinicalSichuan Baili Pharmaceutical Co LtdGlioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours
Details
SKB-337SKB337; A-337; SKB-337Phase 1 ClinicalSichuan Kelun-Biotech Biopharmaceutical Co LtdSolid tumours
Details
IMM2505IMM2505; IMM-2505Phase 1 ClinicalSunHo (China) BioPharmaceutical Co LtdSolid tumours
Details
QLS31901QLS-31901; QLS31901Phase 1 ClinicalQilu Pharmaceutical Co LtdNeoplasms
Details
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityPeritoneal Neoplasms; Pleural Effusion, Malignant
Details
CCX-559CCX-559Phase 1 ClinicalChemocentryx IncNeoplasms; Solid tumours
Details
RagistomigABL-503; TJ-L14B/ABL503; ABL503; TJ-L14BPhase 1 ClinicalI-Mab Biopharma Co LtdSolid tumours
Details
GS-19GT-90008; GS-19; GS-19-PLB-1CPhase 1 ClinicalGensun Biopharma IncSolid tumours
Details
TST-005TST-005; TST005Phase 1 ClinicalSuzhou Transcenta Therapeutics Co LtdNeoplasms; Papillomavirus Infections; Solid tumours
Details
BR-102BR102Phase 1 ClinicalZhejiang BioRay Biopharmaceuticals Co LtdNeoplasms; Solid tumours
Details
AN-4005AN-4005Phase 1 ClinicalHangzhou Adlai Nortye Biopharma Co LtdLymphoma; Neoplasms; Solid tumours
Details
PF-07257876Phase 1 ClinicalPfizer IncCarcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
TT-00420/AtezolizumabPhase 1 ClinicalTransThera Sciences (Nanjing) IncGastrointestinal Neoplasms
Details
IMM-2520IMM-2520Phase 1 ClinicalBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
FS222 mAb² (F-star Therapeutics)FS-222Phase 1 ClinicalF-star Beta LtdNeoplasm Metastasis; Neoplasms; Solid tumours
Details
Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical)BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1Phase 1 ClinicalWuhan Binhui Biotechnology Co LtdMelanoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms
Details
CN-202CN-202Phase 1 ClinicalCuron Biopharmaceutical LtdHematologic Neoplasms; Solid tumours
Details
SHS-009SHS-009; SH009; SH-009Phase 1 ClinicalNanjing Sanhome Pharmaceutical Co Ltd Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Liver Neoplasms; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
Gallium [68Ga] Natan recombinant PD-L1 single domain antibodySNA-002; 68Ga-NOTA-SNA002Phase 1 ClinicalSmartnuclide BiopharmaContrast agents; Neoplasms; Solid tumours
Details
CHECKvaccCF33-hNIS-antiPDL1Phase 1 ClinicalCity Of Hope National Medical Center, Imugene LtdBreast Neoplasms; Metastatic breast cancer; Triple Negative Breast Neoplasms
Details
SG-1408SG-1408; SG1408Phase 1 ClinicalHangzhou Shangjian Biotechnology Co LtdSolid tumours
Details
CS-23546CS-23546; CS23546Phase 1 ClinicalShenzhen Chipscreen Biosciences Co LtdImmune System Diseases; Neoplasms
Details
BPI-371153BPI-371153Phase 1 ClinicalBetta Pharmaceuticals Co LtdCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lymphoma; Solid tumours
Details
ASC-61ASC-61Phase 1 ClinicalAscletis Pharma IncNeoplasms; Solid tumours
Details
QL-415QL-415Phase 1 ClinicalQlsf Biotherapeutics IncNeoplasms
Details
HS-10386HS-10386Phase 1 ClinicalJiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co LtdSolid tumours
Details
HBM-9027HBM-9027; HBM9027Phase 1 ClinicalHarbour BiomedNeoplasms; Solid tumours
Details
Ori-Bs-001Ori-Bs-001Phase 1 ClinicalOriCell Therapeutics Co LtdSolid tumours
Details
Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityAscites; Serositis
Details
RAD-203RAD-203Phase 1 ClinicalRadiopharm Theranostics LtdCarcinoma, Non-Small-Cell Lung
Details
177Lu-RAD204177Lu-anti-PD-L1 sdAb; RAD-204; 177Lu-RAD204Phase 1 ClinicalRadiopharm Theranostics LtdCarcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Mismatch Repair Deficient Cancer; Skin Melanoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
AUR-106AUR-106Phase 1 ClinicalAurigene Discovery Technologies LtdCarcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colonic Neoplasms; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Stomach Neoplasms
Details
Recombinant anti-PD-L1/TGF-β bifunctional fusion proteinPhase 1 ClinicalHualan Genetic Engineering (Henan) Co LtdSolid tumours
Details
B-901B-901; B901Phase 1 ClinicalFutureGen Biopharm (Beijing) Co LtdSolid tumours
Details
KM602KM602; KM-602; XZP-KM602Phase 1 ClinicalXuanzhu (Shijiazhuang) Biotechnology Co LtdSolid tumours
Details
MAX-001MAX-001; MAX001Phase 1 ClinicalInflamax Pharmaceuticals (Guangzhou) Co LtdSolid tumours
Details
ND-021ND-021; NM21-1480; CS-2006; CS2006Phase 1 ClinicalCstone Pharmaceuticals, Numab Therapeutics AgCarcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
SM-2275SM-2275; SM2275Phase 1 ClinicalZhuhai StarMab BioMed Technology LtdSolid tumours
Details
BAT-7205BAT7205; BAT-7205Phase 1 ClinicalBio-Thera Solutions LtdNeoplasm Metastasis; Solid tumours
Details
YL-222YL222; YL-222Phase 1 ClinicalMediLink Therapeutics Co LtdSolid tumours
Details
PMI-06PMI-06; PMI06; 18F-DK222; [18F]DK-222Phase 1 ClinicalPrecision Molecular IncCarcinoma, Non-Small-Cell Lung
Details
A-337 (Klus Pharma)A337 (Klus Pharma); A-337 (Klus Pharma)Phase 1 ClinicalKlus Pharma IncNeoplasms
Details
LW-347LW-347Phase 1 ClinicalShanghai Longwood Biopharmaceuticals Co LtdNeoplasms
Details
JSKN-022JSKN022; JSKN-022Phase 1 ClinicalAlphamab OncologyNeoplasms; Solid tumours
Details
BHP-01BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-TPhase 1 ClinicalChengdu Brilliant Pharmaceutical Co LtdSmall Cell Lung Carcinoma
Details
XB-628XB628Phase 1 ClinicalExelixis IncNeoplasms; Solid tumours
Details
DCR-PDL1DCR-PDL1Phase 1 ClinicalDicerna Pharmaceuticals IncSolid tumours
Details
Naptumomab estafenatox/DurvalumabNTX-352Phase 1 ClinicalNeotx Therapeutics LtdSolid tumours
Details
BMS-986238BMS-986238Phase 1 ClinicalBristol-Myers Squibb Belgium SaLymphoma; Solid tumours
Details
PF-08046037PF-08046037; SGN-PDL1iTPhase 1 ClinicalPfizer IncCarcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
JSKN-027JSKN027; JSKN-027Phase 1 ClinicalAlphamab OncologyNeoplasms; Solid tumours
Details
[18F]DK222[18F]DK-222; [18F]DK222Phase 1 ClinicalSidney Kimmel Comprehensive Cancer CenterCarcinoma; Carcinoma, Non-Small-Cell Lung
Details
68Ga-NOTA-WL12Phase 1 ClinicalBeijing Cancer HospitalCarcinoma, Non-Small-Cell Lung
Details
188Re-NM-01188Re-NM-01Phase 1 ClinicalNanomab Technology LtdLung Neoplasms
Details
VSV-02VSV-02Phase 1 ClinicalJoint Biosciences LtdBreast Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Solid tumours
Details
ReozalimabIBI-318; LY-3434172; LY3434172Phase 1 ClinicalEli Lilly And CompanyCarcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lymphoma, Extranodal NK-T-Cell; Neoplasms; Small Cell Lung Carcinoma
Details
Pd-1-pikPd-1-pikPhase 1 ClinicalHuashan Hospital Affiliated To Fudan UniversityGlioblastoma
Details
IBC-Ab002IBC-Ab002Phase 1 ClinicalImmunoBrain Checkpoint IncAlzheimer Disease
Details
CTX-8371CTX-8371Phase 1 ClinicalCompass Therapeutics LLCCarcinoma, Non-Small-Cell Lung; Hodgkin Disease; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
ABL-501ABL-501Phase 1 ClinicalAbl Bio IncSolid tumours
Details
IMGS-001IMGS-001Phase 1 ClinicalThe University Of Texas MD Anderson Cancer CenterColorectal Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
PEC-QTPEC-QT; VCTX-210Phase 1 ClinicalCrispr Therapeutics Ag, Viacyte IncAutoimmune Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Endocrine System Diseases; Glucose Metabolism Disorders; Immune System Diseases; Metabolic Diseases
Details
Q-1801Q-1801; Q 1801Phase 1 ClinicalQure Biotechnology (Shanghai) Co LtdSolid tumours
Details
HLX-37HLX37; HLX-37Phase 1 ClinicalShanghai Henlius Biotech IncCarcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasm Metastasis; Solid tumours; Triple Negative Breast Neoplasms
Details
QL-301QL-301Phase 1 ClinicalQlsf Biotherapeutics IncNeoplasms
Details
XirestomigATG-101; ATG101; YN051Phase 1 ClinicalThe Origin Cell Technology Group Co LtdHematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Solid tumours
Details
BH-3120BH-3120Phase 1 ClinicalHanmi Pharmaceutical Co LtdSolid tumours
Details
TS-1905TS-1905; LY-01019; BA-1201Phase 1 ClinicalShandong Boan Biotechnology Co LtdSolid tumours
Details
CYTO-102CYTO-NK-102; CYTO-102; COH06Phase 1 ClinicalCytoImmune Therapeutics IncCarcinoma, Non-Small-Cell Lung; Lung Neoplasms
Details
EMB-09EMB-09Phase 1 ClinicalShanghai Epimab Biotherapeutics, IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hepatitis B, Chronic; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
AN-8025AN-8025Phase 1 ClinicalHangzhou Adlai Nortye Biopharma Co LtdSolid tumours
Details
LP-008LP-008Phase 1 ClinicalLepu Biopharma Co LtdSolid tumours
Details
SIM-0237SIM-0237; SIM-237Phase 1 ClinicalSimcere Pharmaceutical Group LtdSolid tumours; Urinary Bladder Neoplasms
Details
AB-101 (Arbutus Biopharma)AB-101 (Arbutus Biopharma)Phase 1 ClinicalArbutus Biopharma CorpHepatitis B; Hepatitis B, Chronic
Details
anti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine)Phase 1 ClinicalShanghai Unicar-Therapy Bio-Medicine Technology Co LtdHormone-Resistant Prostate Neoplasms
Details
anti-PD-L1 CSR T-cell therapy (Marino Biotechnology)Phase 1 ClinicalBeijing Marino Biotechnology Co LtdGlioblastoma; Neoplasms
Details
dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityCarcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms
Details
SimridarlimabIBI-322; IBI322Phase 1 ClinicalBone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell; Neoplasms; Solid tumours
Details
IMMH-010IMMH-010Phase 1 ClinicalTianjin Chase Sun Pharmaceutical Co LtdNeoplasms; Solid tumours
Details
OpucolimabHLX-20Phase 1 ClinicalNeoplasms; Solid tumours
Details
INCB-086550INCB-086550; INCB-86550Phase 1 ClinicalIncyte CorpCarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Solid tumours
Details
MCLA-145MCLA-145Phase 1 ClinicalIncyte Corp, Merus NvLymphoma, B-Cell; Neoplasms; Solid tumours
Details
LOR-S03CDX-527Phase 1 ClinicalCelldex TherapeuticsBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms
Details
SL-279252TAK-252; SL-279252Phase 1 ClinicalShattuck Labs Inc, Takeda Pharmaceutical Co LtdAdenocarcinoma; Astrocytoma; Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
LodapolimabLY-3300054Phase 1 ClinicalEli Lilly And CompanyBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Microsatellite instability-high cancer; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours; Triple Negative Breast Neoplasms
Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech)Z-CTLsPhase 1 ClinicalHunan Zhaotai Yongren Biotech Co LtdCarcinoma, Non-Small-Cell Lung
Details
EmdifenPhase 1 ClinicalChinese Academy Of Medical Sciences, Tianjin Chase Sun Pharmaceutical Co LtdSolid tumours
Details
LesabelimabBC-003; ADG-104Phase 2 ClinicalAdagene (Suzhou) Ltd, Baifan Biotechnology (Shanghai) Co Ltd, Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co LtdCarcinoma, Renal Cell; Neoplasms; Penile Neoplasms; Urinary Bladder Neoplasms
Details
ABSK-043ABSK043Phase 2 ClinicalABbisko Therapeutics Co LtdCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Neoplasms; Sarcoma; Solid tumours
Details
PM-8003PM8003Phase 2 ClinicalSolid tumours
Details
PM-1003PM1003Phase 2 ClinicalSolid tumours
Details
Palverafusp alfaIMM-2510; SYN-2510; AXN-2510Phase 2 ClinicalCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasms; Sarcoma; Solid tumours; Triple Negative Breast Neoplasms
Details
PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital)Phase 2 ClinicalShanghai Zhongshan HospitalCholangiocarcinoma
Details
HLX-301HLX-301Phase 2 ClinicalCarcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lymphoma; Neoplasm Metastasis; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
Q-1802Q-1802Phase 2 ClinicalQure Biotechnology (Shanghai) Co LtdEsophageal Neoplasms; Gastrointestinal Neoplasms; Solid tumours
Details
6MW-32116MW3211; 6MW-3211Phase 2 ClinicalMabwell (Shanghai) Bioscience Co LtdCarcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Myelodysplastic Syndromes; Neoplasms
Details
Recombinant anti-PD-L1/TGF-β bispecific antibodyY101D; Y-101DPhase 2 ClinicalWuhan Yzy Biopharma Co LtdCarcinoma, Hepatocellular; Pancreatic Neoplasms; Solid tumours
Details
CarrizumabPhase 2 ClinicalJiangsu Hengrui Medicine Co LtdAdenocarcinoma; Esophageal Neoplasms; Stomach Neoplasms
Details
NebratamigGNC-035Phase 2 ClinicalSichuan Baili Pharmaceutical Co LtdBreast Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Solid tumours
Details
FH-2001FH-2001Phase 2 ClinicalSolid tumours
Details
INCB-099280INCB-099280; INCB-99280Phase 2 ClinicalIncyte Corp LtdCarcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Mesothelioma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms
Details
QLF31907QLF31907; QLF-31907Phase 2 ClinicalQilu Pharmaceutical Co LtdCarcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Solid tumours
Details
IBC-0966IBC-0966Phase 2 ClinicalNeoplasms
Details
OpamtistomigLBL-024; LBL024Phase 2 ClinicalNanjing Leadsbiolabs Co LtdCarcinoma, Neuroendocrine; Melanoma; Neoplasms; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
BAT-7104BAT-7104Phase 2 ClinicalBio-Thera Solutions LtdNeoplasms; Solid tumours
Details
BCD-106BCD-106Phase 2 ClinicalBIOCAD JSCSolid tumours
Details
706-3SBioSSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibodyPhase 2 Clinical3sbio IncCarcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Composite Lymphoma; Digestive System Neoplasms; Esophageal Neoplasms; Lymphoma; Neoplasms; Solid tumours
Details
DR-30206DR-30206Phase 2 ClinicalZhejiang Doer Biologics CorpCarcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
PM-1022PM-1022Phase 2 ClinicalNeoplasms
Details
HB-0028HB-0028Phase 2 ClinicalHuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co LtdSolid tumours; Uterine Cervical Neoplasms
Details
99mTc-NM-0199mTc-NM-01Phase 2 ClinicalNanomab Technology LtdCarcinoma, Non-Small-Cell Lung
Details
EmfizatamabGNC-038Phase 2 ClinicalSichuan Baili Pharmaceutical Co Ltd, SystImmuneArthritis, Rheumatoid; Central Nervous System Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours
Details
AP-505AP-505; B1962; AP505Phase 2 ClinicalAP Biosciences IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
18F-BMS-98622918F-BMS-986229; [18F]BMS-986229Phase 2 ClinicalBristol-Myers Squibb International Corp, PeptiDream IncAdenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Stomach Neoplasms
Details
6MW-35116MW-3511Phase 2 ClinicalMabwell (Shanghai) Bioscience Co LtdNeoplasms; Solid tumours
Details
AB-001 (Agastiya Biotech)AB01 (Agastiya Biotech); AB001 (Agastiya Biotech); AB-01 (Agastiya Biotech)Phase 2 ClinicalAgastiya Biotech LLCNeoplasms
Details
HK-010HK-010; HK010Phase 2 ClinicalAnhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co LtdNeoplasms; Solid tumours
Details
LB-101 (Centessa Pharmaceuticals)LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibodyPhase 2 ClinicalCentessa Pharmaceuticals PlcSolid tumours
Details
BPB-101BPB-101Phase 2 ClinicalBetta Pharmaceuticals Co LtdSolid tumours
Details
PacmilimabCX-072Phase 2 ClinicalCytomx Therapeutics IncBreast Neoplasms; Lymphoma; Melanoma; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
PRS-344PRS-344S095012; S-095012; S-95012; PRS-344/ONC0055; PRS-344; PRS-344/S095012Phase 2 ClinicalPieris Pharmaceuticals IncSolid tumours
Details
MAX-80391MAX-80391; MAX-8Phase 2 ClinicalMaxiNovel Pharmaceuticals Co LtdSolid tumours
Details
SPX-303SPX-303Phase 2 ClinicalSparX Biopharmaceutical CorpBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
JSKN-033JSKN033; JSKN-033; JSKN-003/EnvafolimabPhase 2 ClinicalJiangsu Alphamab Biopharmaceuticals Co LtdCarcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours; Uterine Cervical Neoplasms
Details
SOA-101SOA-101; SOA101Phase 2 ClinicalShine-On BioMedical Co LtdBrain Neoplasms; Breast Neoplasms; Lung Neoplasms; Mouth Neoplasms; Ovarian Neoplasms; Solid tumours
Details
CVL006CVL006; B006Phase 2 ClinicalConvalife (Shanghai) Co LtdNeoplasms; Solid tumours
Details
DB-1419DB-1419Phase 2 ClinicalDuality Biologics (Suzhou) Co LtdSolid tumours
Details
IBI-3014IBI3014; IBI-3014Phase 2 ClinicalSolid tumours
Details
HY-05350HY-0005; HY-05350Phase 2 ClinicalSichuan Huiyu Seacross Pharma Technology LtdBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
[18F]AlF-NOTA-PCP218F-AlF-NOTA-PCP2Phase 2 ClinicalShandong First Medical UniversityCarcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Glioblastoma; Squamous Cell Carcinoma of Head and Neck
Details
SKB-103SKB103; SKB-103Phase 2 ClinicalSichuan Kelun-Biotech Biopharmaceutical Co LtdSolid tumours
Details
HB-0036HB-0036Phase 2 ClinicalHuaBo Biopharm Co LtdCarcinoma, Non-Small-Cell Lung; Solid tumours
Details
AP-203AP-203; AP203Phase 2 ClinicalAP Biosciences IncCarcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology)LP-002Phase 2 ClinicalTaizhou Houde Aoke Technology Co LtdCarcinoma, Squamous Cell; Digestive System Neoplasms; Melanoma; Primary mediastinal B cell lymphoma; Small Cell Lung Carcinoma; Solid tumours
Details
Type 1 diabetes stem cell gene therapy (Altheia Science)Phase 2 ClinicalAltheia Science SrlDiabetes Mellitus, Type 1
Details
DanburstotugSTI-3031; STI-A1015; IMC-001Phase 2 ClinicalSorrento Therapeutics IncBiliary Tract Neoplasms; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Neoplasm Metastasis; Neoplasms; Solid tumours
Details
89Zr-durvalumabPhase 2 ClinicalRadboud University NijmegenCarcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms
Details
EvixapodlinGS-4224; OX-4224Phase 2 ClinicalGilead Sciences IncCarcinoma, Non-Small-Cell Lung; Solid tumours
Details
BetifisolimabMSB-2311Phase 2 ClinicalSuzhou Transcenta Therapeutics Co LtdSolid tumours
Details
PM-80016MW3111; PM-8001Phase 2 ClinicalCarcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms; Solid tumours
Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital)Phase 2 ClinicalChanghai Hospital of Navy Medical UniversityPancreatic Neoplasms
Details
BMS-936559MDX-1105; BMS-936559Phase 2 ClinicalBristol-Myers Squibb CompanyColonic Neoplasms; Colorectal Neoplasms; HIV Infections; Hodgkin Disease; Leukemia, Myelogenous, Chronic; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasms; Rectal Neoplasms; Sepsis; Shock, Septic; Small Cell Lung Carcinoma
Details
CadapersenRG-6084; RO-7191863Phase 2 ClinicalF. Hoffmann-La Roche LtdHepatitis B; Hepatitis B, Chronic
Details
VudalimabXmAb-717; XmAb-20717; XmAb 717Phase 2 ClinicalXencor IncAdenocarcinoma, Clear Cell; Adenoma, Acidophil; Adnexal Diseases; Astrocytoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Castration-Sensitive Prostate Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms
Details
Durvalumab/GefitinibPhase 2 ClinicalMedimmuneCarcinoma, Non-Small-Cell Lung
Details
RC-98RC-98; RC98; RC98-ADCPhase 2 ClinicalSolid tumours; Stomach Neoplasms
Details
PD-L1 t-haNK cell therapyPhase 2 ClinicalNantkwest IncEsophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
89Zr-DFO-Atezolizumab89Zr-DFO-AtezolizumabPhase 2 ClinicalUniversity of Texas Southwestern Medical CenterCarcinoma, Renal Cell; Diagnostic agents; Lymphoma, B-Cell
Details
MAX-10181MAX-1; MAX-10181; MX-10181Phase 2 ClinicalMaxiNovel Pharmaceuticals Co LtdGlioblastoma; Glioma; Neoplasms; Solid tumours
Details
FAZ-053FAZ-053; LAE-005; LAE005Phase 2 ClinicalNovartis Pharma AgChordoma; Sarcoma, Alveolar Soft Part; Solid tumours; Triple Negative Breast Neoplasms
Details
PumitamigPM-8002; BMS-986545; PM8002; BNT-327Phase 3 ClinicalBreast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Metastatic breast cancer; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
HL-301HL-301Phase 3 ClinicalHanmi Pharmaceutical Co LtdAcute Bronchitis; Lung Neoplasms; Pulmonary Disease, Chronic Obstructive; Radiation Pneumonitis
Details
Sotiburafusp alfaHB0025; HB-0025Phase 3 ClinicalHuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co LtdCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hematologic Neoplasms; Kidney Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
CA-170CA-170; AUPM-170Phase 3 ClinicalAurigeneCarcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours
Details
SHS-006(Nanjing Sanhome Pharmaceutical)SHS-006; SH-006; SH006Phase 3 ClinicalNanjing Sanhome Pharmaceutical Co Ltd Carcinoma, Hepatocellular; Liver Neoplasms; Solid tumours
Details
SGN-PDL1VSGN-PDL1V; PF-08046054Phase 3 ClinicalSeagen IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
LB-1410LB-1410Phase 3 ClinicalL&L Biopharma Co LtdLymphoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms
Details
HLX-43HLX-43; HLX43Phase 3 ClinicalShanghai Henlius Biotech IncBreast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
ErfonrilimabKN-046Phase 3 ClinicalJiangsu Alphamab Biopharmaceuticals Co LtdBiliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Lymphoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Triple Negative Breast Neoplasms
Details
Bintrafusp alfaM-7824; GSK-4045154; MSB-0011359CPhase 3 ClinicalMerck SeronoAnus Neoplasms; Biliary Tract Neoplasms; Brain metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Esthesioneuroblastoma, Olfactory; Gallbladder Neoplasms; Ganglioglioma; Head and Neck Neoplasms; Hematologic Neoplasms; Intestinal Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Microsatellite Instability; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nose Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Penile Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Respiratory papillomatosis; Sarcoma; Sarcoma, Kaposi; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymic epithelial tumor; Thymoma; Thymus Neoplasms; Triple Negative Breast Neop
Details
PD-1 Inhibitor Therapy(Hunan Cancer Hospital)Hunan Cancer Hospital
Details
TreprilimabClinicalSun Yat-Sen UniversityOropharyngeal Neoplasms
Details
INSIX RA (Indus Biotech)ClinicalIndus Biotech Pvt LtdArthritis, Rheumatoid; Inflammation
Details
64Cu-DOTA-nivolumab (Bristol-Myers Squibb/Ono Pharmaceutical)ClinicalBristol-Myers Squibb Company, Ono Pharmaceutical Co LtdCarcinoma, Non-Small-Cell Lung; Melanoma
Details
PD-1 gene engineered T cell therapy(Meijesell Biotechnology)Phase 1 ClinicalChengdu Medgencell, West China Hospital Of Sichuan UniversityCarcinoma, Non-Small-Cell Lung
Details
Rituximab/PaclitaxelAR-160Phase 1 ClinicalMayo ClinicLeukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin
Details
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology)Phase 1 ClinicalAnhui Korton Biological Technology Co LtdCarcinoma, Hepatocellular; Esophageal Neoplasms
Details
STW204STW-204; AI025; AI-025Phase 1 ClinicalSuzhou Stainwei Biotech IncNeoplasms; Solid tumours
Details
MW-11MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111Phase 1 ClinicalMabwell (Shanghai) Bioscience Co LtdBreast Neoplasms; Solid tumours
Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical)Phase 1 ClinicalShanxi Weiqidaguangming Pharmaceutical Co LtdSolid tumours
Details
αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd)BZDS1901; BZDS-1901; BZD1901Phase 1 ClinicalShanghai Cell Therapy Group Co LtdCarcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Mesothelioma; Ovarian Neoplasms; Solid tumours
Details
VT1093VT1093; VT-1093Phase 1 ClinicalBeijing Weiyuan Likang Biotechnology Co LtdSolid tumours
Details
NWY-001(Biocytogen Pharmaceuticals)NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals)Phase 1 ClinicalHematologic Neoplasms; Neoplasms; Solid tumours
Details
IBI-319IBI-319Phase 1 ClinicalNeoplasms
Details
GNR-051GNR-051Phase 1 ClinicalGenerium PharmaceuticalsCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma
Details
JS-201JS-201Phase 1 ClinicalShanghai Junshi Biosciences Co LtdNeoplasms
Details
PH-762PH-762; PH762-ACT; RXI 762-ACT; mPH-762; PH762-TMEPhase 1 ClinicalPhio Pharmaceuticals CorpBreast Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Melanoma; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Urogenital Neoplasms
Details
IBI-321IBI-321Phase 1 ClinicalNeoplasms; Solid tumours
Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)Phase 1 ClinicalSecond Affiliated Hospital Of Zhejiang University School Of MedicineLymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma
Details
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals)Bis-5Phase 1 ClinicalL&L Biopharma Co LtdNeoplasms; Solid tumours; Uterine Cervical Neoplasms
Details
SHR-1901SHR-1901Phase 1 ClinicalSuzhou Suncadia Biopharmaceuticals Co LtdNeoplasms
Details
Recombinant human anti-PD-1 monoclonal antibody(Hec Biological)Phase 1 ClinicalDongguan City Hec Biological Medicine Res And Development Co LtdEsophageal adenocarcinoma; Stomach Neoplasms
Details
LatikafuspAMG-256Phase 1 ClinicalAmgen IncSolid tumours
Details
89Zr-N-sucDf-pembrolizumabPhase 1 ClinicalMerck & Co Inc, Umcg The University Medical Center GroningenCarcinoma, Non-Small-Cell Lung; Melanoma
Details
AK-131AK-131Phase 1 ClinicalNeoplasms; Solid tumours
Details
CDX-585CDX-585; BSI-585Phase 1 ClinicalBiosion Inc, Celldex TherapeuticsCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms
Details
ABBV-1882ABBV-1882Phase 1 ClinicalAbbvie IncHIV Infections
Details
Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University)Phase 1 ClinicalSun Yat-Sen UniversityHematologic Neoplasms; Nasopharyngeal Carcinoma
Details
SOT-201SOT-201; SO C108; SO-C108Phase 1 ClinicalSotioNeoplasms; Solid tumours
Details
Sym-024Sym-024; S-95024Phase 1 ClinicalSymphogen A/SNeoplasm Metastasis; Solid tumours
Details
KY-0118KY-0118; KY0118Phase 1 ClinicalNovatim Immune Therapeutics (Zhejiang) Co LtdCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
JNJ-67484703JNJ-67484703; JNJ-4703Phase 1 ClinicalJanssen Research & Development LlcArthritis, Rheumatoid
Details
BC008-1ABC008-1APhase 1 ClinicalSichuan Luzhou Buchang Biopharmaceutical Co LtdCarcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Glioblastoma; Glioma; Solid tumours
Details
WTX-212WTX-212Phase 1 ClinicalWestlake TherapeuticsHematologic Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours
Details
HBT-708HBT-708; SSGJ-708Phase 1 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdGastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
Details
STW204/GotistobartAI-061Phase 1 ClinicalOncoc4 IncAnus Neoplasms; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
MAX-001MAX-001; MAX001Phase 1 ClinicalInflamax Pharmaceuticals (Guangzhou) Co LtdSolid tumours
Details
TEV-56278TEV-56278Phase 1 ClinicalTeva Pharmaceutical Industries LtdMelanoma; Neoplasms; Solid tumours
Details
WTX-212AWTX-212A; WTX212APhase 1 ClinicalZhejiang UniversityNeoplasms; Solid tumours
Details
BAT-3306BAT3306; BAT-3306Phase 1 ClinicalBio-Thera Solutions LtdCarcinoma, Non-Small-Cell Lung
Details
Pembrolizumab Biosimilar(Sandoz)GME-751; GME751Phase 1 ClinicalSandozCarcinoma, Non-Small-Cell Lung; Melanoma
Details
BPT-567BPT-567Phase 1 ClinicalBright Peak Therapeutics IncNeoplasms; Solid tumours
Details
PD 1-proIL-2v (Proviva Therapeutics)PTX-912Phase 1 ClinicalProviva Therapeutics IncNeoplasm Metastasis; Neoplasms; Solid tumours
Details
S-4321S-4321Phase 1 ClinicalSeismic Therapeutics IncArthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; Dermatitis, Atopic; Immune System Diseases; Lupus Erythematosus, Cutaneous; Psoriasis
Details
P-1801P-1801Phase 1 ClinicalPharmaEssentia CorpSolid tumours
Details
BZE-2209BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T CellsPhase 1 ClinicalShanghai Cell Therapy Group Co LtdSolid tumours
Details
IMC-S118AIIMC-S118AIPhase 1 ClinicalImmunocore Holdings PLCDiabetes Mellitus, Type 1
Details
GB-268GB268Phase 1 ClinicalGenor Biopharma Co LtdNeoplasms; Solid tumours
Details
CD-001CD-001Phase 1 ClinicalCD (Suzhou) Biopharma Co LtdHead and Neck Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Solid tumours
Details
γδ T-PD-1 Ab Cells therapy(Changzhou No.2 People’S Hospital)Phase 1 ClinicalChangzhou No.2 People’S HospitalMeningioma; Solid tumours
Details
SSGJ-709SSGJ-709; SSGJ709Phase 1 ClinicalShenyang Sunshine Pharmaceutical Co LtdNeoplasms; Solid tumours
Details
TQB-2252TQB-2252; TQB2252Phase 1 ClinicalChia Tai Tianqing (Guangzhou) Pharmaceutical Co LtdNeoplasms; Solid tumours
Details
MAQ-001MAQ-001Phase 1 ClinicalMabQuest SASolid tumours
Details
FP-008 (Fapon Biotech)FP-008; FP008Phase 1 ClinicalGuangdong Fapon Biopharma IncNeoplasms; Solid tumours
Details
SA-1211SA-1211Phase 1 ClinicalSuzhou Siran Biotech Co LtdHepatitis B; Hepatitis B, Chronic
Details
TEV-278TEV-278; TEV-‘278Phase 1 ClinicalTeva Pharmaceutical Industries LtdNeoplasms
Details
CTX-10726CTX-10726Phase 1 ClinicalCompass Therapeutics IncCarcinoma, Hepatocellular; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Neoplasms; Solid tumours
Details
ONO-4915ONO-4915Phase 1 ClinicalOno Pharmaceutical Co LtdAutoimmune Diseases
Details
JLM-019JLM-019Phase 1 ClinicalJecho Biopharmaceuticals Co LtdLymphoma; Solid tumours
Details
IBI-3026IBI3026; IBI-3026Phase 1 ClinicalNeoplasms; Solid tumours
Details
KH-813KH813; KH-813Phase 1 ClinicalChengdu Kanghong Biotechnologies Co LtdCarcinoma, Non-Small-Cell Lung
Details
Pembrolizumab biosimilar (Shanghai Hongcheng Pharma)Phase 1 ClinicalShanghai Hongcheng Pharmaceutical Co LtdBile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Microsatellite instability-high cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
Pembrolizumab biosimilar (Hualan Genetic Engineering)Phase 1 ClinicalHualan Ankang Biotechnology Co LtdBile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
HLX-18HLX-18; HLX18Phase 1 ClinicalSolid tumours
Details
TQB-6457TQB-6457; TQB6457Phase 1 ClinicalShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co LtdNeoplasms
Details
Anti-PD1 armored CD19 CAR-T cells therapy (Topcel-KH Pharmaceutical)Phase 1 ClinicalJiangsu Topcel-KH Pharmaceutical Co LtdLymphoma, Large B-Cell, Diffuse
Details
Pembrolizumab biosimilar (Alvotech Swiss)AVT32-DRL_PBPhase 1 ClinicalAlvotech Swiss AgMelanoma
Details
ReozalimabIBI-318; LY-3434172; LY3434172Phase 1 ClinicalEli Lilly And CompanyCarcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lymphoma, Extranodal NK-T-Cell; Neoplasms; Small Cell Lung Carcinoma
Details
CTX-8371CTX-8371Phase 1 ClinicalCompass Therapeutics LLCCarcinoma, Non-Small-Cell Lung; Hodgkin Disease; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
HY-0007HY-0007Phase 1 ClinicalSichuan Huiyu Pharmaceutical Co LtdCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours
Details
GS-0151GS-0151; MB-151Phase 1 ClinicalUniversity Of OxfordArthritis, Rheumatoid; Autoimmune Diseases; Inflammation
Details
iCasp9M28z T cellsPhase 1 ClinicalMemorial Sloan Kettering Cancer CenterBreast Neoplasms; Lung Neoplasms; Mesothelioma
Details
rHSV-1-APD1YST-02Phase 1 ClinicalXiamen UniversityCentral Nervous System Neoplasms; Glioma; Neoplasms; Solid tumours
Details
MHC-001MHC-001Phase 1 ClinicalSichuan UniversityCarcinoma, Non-Small-Cell Lung
Details
Sofusa anti-PD-1Phase 1 ClinicalSorrento Therapeutics IncLymphoma, T-Cell, Cutaneous
Details
Yinkang-001Phase 1 ClinicalYinkang Biopharma Inc.Solid tumours
Details
PD-1 antibody (Boehringer Ingelheim International)Phase 1 ClinicalBoehringer Ingelheim International GmbhImmune System Diseases
Details
engineered TILs expressing anti PD-1 antibody (Shanghai Cell Therapy Group/Shanghai Cell Therapy Research Institute)PD1-TILPhase 1 ClinicalShanghai Cell Therapy Research InstituteGlioblastoma
Details
triple anti-CD19 CAR T-cell therapy/PD-1 checkpoint inhibitor/IL-21 receptor agonist (CD (Suzhou) Biopharma/Chinese People's Liberation Army General Hospital/Chinese academy of sciences)Phase 1 ClinicalChinese Academy Of SciencesHematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
TaminadenantNIR-178; PBF-509Phase 1 ClinicalPalobiofarma SlCarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Parkinson Disease; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Triple Negative Breast Neoplasms
Details
Nivolumab(Mabpharm)CMAB8-19; CMAB-819Phase 1 ClinicalSinomab Bioscience LtdCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck
Details
RB-0004RB-0004Phase 1 ClinicalReyoung Pharmaceutical Co LtdLymphoma; Solid tumours
Details
BesufetamigONO-4685Phase 1 ClinicalMerus NvLeukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Plaque psoriasis
Details
Sym-021Sym-021; S-95016; Sym021Phase 1 ClinicalSymphogen A/SLymphoma; Neoplasm Metastasis; Solid tumours
Details
IzuralimabXmAb-23104; XmAb-104Phase 1 ClinicalXencor IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania)LXF-821Phase 1 ClinicalNovartis Pharma Ag, University Of PennsylvaniaGlioblastoma
Details
Eciskafusp AlfaRO-7284755; RG-6279; PD1-IL2vPhase 1 ClinicalF. Hoffmann-La Roche AgSolid tumours; Urinary Bladder Neoplasms
Details
CC-90006C-90006; CC-90006Phase 1 ClinicalAnaptysbio IncAutoimmune Diseases; Psoriasis
Details
ZeluvalimabAMG-404Phase 1 ClinicalAmgen IncPrecursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms, Castration-Resistant; Small Cell Lung Carcinoma; Solid tumours
Details
FidasimtamabIBI-315; BH-2950Phase 1 ClinicalHanmi Pharmaceutical Co LtdNeoplasms; Solid tumours
Details
SYN-125SYN-125Phase 1 ClinicalSynermore Biologics (Suzhou) Co LtdCarcinoma; Solid tumours
Details
GX-P1GX-P1; PD-L1 hyfcPhase 1 ClinicalGannex Pharma Co LtdAutoimmune Diseases; Rejection of organ transplantation
Details
Recombinant human PD-1 antibody herpes simplex virusPhase 1 ClinicalXiamen University, Yangsheng Tang Co LtdBrain metastases; Carcinoma, Hepatocellular; Central Nervous System Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
HX-009HX-009; HX009-II-02Phase 2 ClinicalWaterstone Hanxbio Pty LtdBile Duct Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Lymphoma; Melanoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
LipustobartLZM-009Phase 2 ClinicalLivzon(Group) Pharmaceutical FactoryCarcinoma, Non-Small-Cell Lung; Solid tumours; Thymoma
Details
SpartalizumabPDR-001Phase 2 ClinicalNovartis Pharma AgAdenocarcinoma; Adenocarcinoma of Lung; Anus Neoplasms; Bone Marrow Diseases; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Chordoma; Colorectal Neoplasms; Digestive System Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Hematologic Diseases; Kidney Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Melanoma; Mesothelioma; Metastatic breast cancer; Multiple Myeloma; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Neoplasms; Neoplasms, Squamous Cell; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Persistent Fetal Circulation Syndrome; Polycythemia
Details
AcrixolimabYBL-006; YBL 006Phase 2 ClinicalY-biologics IncSolid tumours
Details
EMB-02EMB-02Phase 2 ClinicalShanghai Epimab Biotherapeutics, IncSolid tumours
Details
LBL-015LBL-015Phase 2 ClinicalNanjing Leadsbiolabs Co LtdNeoplasms; Solid tumours
Details
PradusinstobartLVGN-3616; SSI-361Phase 2 ClinicalLyvgen Biopharma(HK)LtdCarcinoma, Hepatocellular; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Papillomavirus Infections; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uveal melanoma
Details
SSGJ-705SSGJ-705; 705Phase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdNeoplasms; Solid tumours
Details
PidilizumabMDV-9300; CT-011Phase 2 ClinicalCuretech LtdBreast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Hepatitis C, Chronic; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Melanoma; Multiple Myeloma; Ovarian Neoplasms; Pancreatic Neoplasms; Primary mediastinal B cell lymphoma; Prostatic Neoplasms; Sarcoma
Details
706-3SBioSSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibodyPhase 2 Clinical3sbio IncCarcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Composite Lymphoma; Digestive System Neoplasms; Esophageal Neoplasms; Lymphoma; Neoplasms; Solid tumours
Details
RosnilimabANB-030Phase 2 ClinicalAnaptysbio IncAlopecia Areata; Arthritis, Rheumatoid; Colitis, Ulcerative
Details
IAP-0971IAP-0971Phase 2 ClinicalSunHo (China) BioPharmaceutical Co LtdCarcinoma, Non-Small-Cell Lung; Hepatitis B, Chronic; Neoplasms; Solid tumours; Urinary Bladder Neoplasms
Details
AK-129AK-129Phase 2 ClinicalAdenocarcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
HerinCAR-PD1Phase 2 ClinicalNingbo Cancer HospitalMeningitis, Fungal; Neoplasms; Solid tumours
Details
Anti-CTLA-4/PD-1 expressing EGFR-CAR-TPhase 2 ClinicalShanghai Cell Therapy Research InstituteSolid tumours
Details
EBV-specific TCR-T cell with anti-PD1 auto-secreted elementPhase 2 ClinicalTcrcure Biopharma LtdSquamous Cell Carcinoma of Head and Neck
Details
PeramprizumabPhase 2 ClinicalSun Yat-Sen UniversityNasopharyngeal Carcinoma
Details
TC-N201(TCRCure)TC-N201Phase 2 ClinicalTcrcure Biopharma LtdNeoplasms; Solid tumours
Details
SV-102SV-102; SV102; SYNC-T SV-102Phase 2 ClinicalSyncromune IncProstatic Neoplasms, Castration-Resistant
Details
SAR-445877SAR-445877; KD-050; mut-1N-IL-15/38B2; SAR-877Phase 2 ClinicalKadmon Corporation LlcCarcinoma, Non-Small-Cell Lung; Solid tumours
Details
OSE-279OSE-279Phase 2 ClinicalOse ImmunotherapeuticsCarcinoma, Non-Small-Cell Lung; Lymphoma; Solid tumours
Details
PD-1 Inhibitor Therapy (Gene Key Life)Phase 2 ClinicalBeijing Gene Key Life Technology Co LtdCarcinoma, Hepatocellular
Details
PD-1 Monoclonal Antibody(Sixth Affiliated Hospital Sun Yat-Sen University)Phase 2 ClinicalSixth Affiliated Hospital Sun Yat-Sen UniversityColorectal Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms
Details
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology)Phase 2 ClinicalAnhui Anke Biotechnology (Group) Co LtdCarcinoma, Transitional Cell; Esophageal Neoplasms; Lung Neoplasms; Lymphoma; Neoplasms; Triple Negative Breast Neoplasms
Details
HC-010(Shanghai Hongcheng)HC-010; HC010Phase 2 ClinicalShanghai Hongcheng Pharmaceutical Co LtdCarcinoma, Non-Small-Cell Lung; Solid tumours
Details
MHB-039-AMHB039A; MHB-039-APhase 2 ClinicalMinghui Pharmaceutical (Hangzhou) Co LtdBreast Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours
Details
PD-1 inhibitor therapy(Shanghai Chest Hospital)Phase 2 ClinicalShanghai Chest HospitalEsophageal Neoplasms; Esophageal Squamous Cell Carcinoma
Details
EzabenlimabBI-754091Phase 2 ClinicalC.H. Boehringer Sohn Ag & Co. KgBiliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
Recombinant human anti-PD-1 monoclonal antibody(CSPC Zhongqi Pharma)Phase 2 ClinicalCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdCarcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Solid tumours
Details
Anti-PD-1 Antibody(Jiangxi Provincial Cancer Hospital)Phase 2 ClinicalJiangxi Provincial Cancer HospitalNasopharyngeal Carcinoma
Details
CS-2009CS-2009Phase 2 ClinicalCstone PharmaceuticalsCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms
Details
LM-299LM299; LM-299Phase 2 ClinicalLaNova Medicines LtdNeoplasms; Solid tumours
Details
SCTB-41SCTB41; SCTB-41; SCT-B41Phase 2 ClinicalSinoCelltech LtdCarcinoma, Non-Small-Cell Lung; Solid tumours
Details
HY-07121HY-07121; HY07121Phase 2 ClinicalSichuan Huiyu Seacross Pharma Technology LtdSolid tumours
Details
AI-081AI-081Phase 2 ClinicalOncoc4 IncSolid tumours
Details
GenSci-120GenSci-120; GenSci120Phase 2 ClinicalChangchun GeneScience Pharmaceuticals Co LtdArthritis, Rheumatoid; Autoimmune Diseases; Graft vs Host Disease; Inflammatory Bowel Diseases; Lupus Erythematosus, Systemic; Sjogren's Syndrome
Details
CR-001(crescent biopharma)CR-001; PR-054Phase 2 ClinicalCrescent Biopharma Inc, Paragon Therapeutics IncNeoplasms; Solid tumours
Details
JMT-108JMT-108; JMT108Phase 2 ClinicalShanghai Jmt-Bio IncCarcinoma, Non-Small-Cell Lung; Melanoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours
Details
BPT-958BPT-958; BPT958Phase 2 ClinicalBright Peak Therapeutics IncNeoplasms
Details
BAT-7111BAT7111; BAT-7111Phase 2 ClinicalBio-Thera Solutions LtdSolid tumours
Details
OTP-01OTP-01Phase 2 ClinicalOttimo Pharma LtdNeoplasms; Solid tumours
Details
ApalulizumabPhase 2 ClinicalShanghai Rui Jin HospitalPancreatic Neoplasms
Details
SYS-6090SYS6090; SYS-6090Phase 2 ClinicalJushi Biopharmaceutical Co LtdCarcinoma, Non-Small-Cell Lung; Digestive System Neoplasms; Neoplasms; Small Cell Lung Carcinoma
Details
MVR-C5252C-5252; MVR-C5252; T-5Phase 2 ClinicalImmvira Co LtdBrain Neoplasms; Ganglioglioma; Glioblastoma; Glioma; Solid tumours
Details
SabestomigAZD-7789Phase 2 ClinicalAstraZeneca AgCarcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Neoplasm Metastasis; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
ASKG-915ASKG-915Phase 2 ClinicalAskgene PharmaColorectal Neoplasms; Neoplasms; Solid tumours
Details
AWT-020AWT020; AWT-020; JS213; JS-213Phase 2 ClinicalAnwita Biosciences IncAutoimmune Diseases of the Nervous System; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Solid tumours
Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army)Phase 2 ClinicalPeople'S Liberation Army General Hospital Military ServiceMultiple Myeloma
Details
PD-1 inhibitor peptide (Aurigene)Phase 2 ClinicalAurigene Oncology LtdColonic Neoplasms; Communicable Diseases; Inflammation
Details
TY-101TY101; TY-101Phase 2 ClinicalTayu Huaxia Biotech Medical Group Co LtdLymphoma; Solid tumours
Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute)Phase 2 ClinicalShanghai Cell Therapy Research InstituteNeoplasms
Details
T-3011T-3 (ImmVira Pharma); MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV; B015; B-015Phase 2 ClinicalImmvira Co LtdAscites; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Mesothelioma; Neoplasms; Ovarian Neoplasms; Sarcoma; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms
Details
NilvanstomigZG-005Phase 2 ClinicalGensun Biopharma IncBile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Lymphoma; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms
Details
MiHA-loaded PD-L silenced DC vaccination (Radboud University)Phase 2 ClinicalRadboud University NijmegenColorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Hematologic Neoplasms
Details
LomvastomigRG-7769; RO-7121661; R07121661Phase 2 ClinicalF. Hoffmann-La Roche LtdCarcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Melanoma; Small Cell Lung Carcinoma; Solid tumours
Details
PeresolimabLY-3462817Phase 2 ClinicalEli Lilly And CompanyArthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Connective Tissue Diseases; Immune System Diseases; Joint Diseases; Musculoskeletal Diseases; Psoriasis; Rheumatic Diseases
Details
PD-1 knockout EBV-CTL (Nanjing Medical University)Phase 2 ClinicalNanjing Medical UniversityHodgkin Disease; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Stomach Neoplasms
Details
LorigerlimabMGD-019; AEX1344Phase 2 ClinicalMacrogenics IncAdenocarcinoma, Clear Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Hormone-Resistant Prostate Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Clear Cell Carcinoma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Skin Melanoma; Solid tumours; Uterine Cervical Neoplasms
Details
AbazistobartSSGJ-609A; SSGJ-609-A; 609-APhase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdBreast Neoplasms; Sarcoma; Solid tumours
Details
DanvilostomigSI-B003Phase 2 ClinicalSichuan Baili Pharmaceutical Co LtdBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Metastatic breast cancer; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
TobemstomigRO-7247669Phase 2 ClinicalF. Hoffmann-La Roche LtdBreast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Squamous Cell Carcinoma; Liver Neoplasms; Melanoma; Solid tumours
Details
MAX-10181MAX-1; MAX-10181; MX-10181Phase 2 ClinicalMaxiNovel Pharmaceuticals Co LtdGlioblastoma; Glioma; Neoplasms; Solid tumours
Details
PimivalimabJTX-4014Phase 2 ClinicalJounce Therapeutics IncCarcinoma, Non-Small-Cell Lung; Neoplasms
Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics)ICTCAR-014Phase 2 ClinicalInnovative Cellular Therapeutics Co LtdLymphoma, Non-Hodgkin
Details
PE0105PE-0105Phase 2 ClinicalShanghai Yunyi Health Technology Development Co LtdNeoplasms; Solid tumours
Details
Nivolumab biosimilar (Shandong Boan Biotechnology)LY-01015; BA-1104Phase 3 ClinicalShandong Boan Biotechnology Co LtdCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal adenocarcinoma; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Glioma; Liver Neoplasms; Melanoma; Mesothelioma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
RC-148RC-148Phase 3 ClinicalBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Solid tumours; Stomach Neoplasms
Details
Mavezelimab/PembrolizumabMK-4280A; MK-4820APhase 3 ClinicalMerck Sharp & Dohme CorpCarcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hodgkin Disease; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours
Details
Pembrolizumab/QuavonlimabMK-1308APhase 3 ClinicalMerck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D(China)Co LtdCarcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Small Cell Lung Carcinoma; Solid tumours
Details
RilvegostomigAZD-2936Phase 3 ClinicalAstrazeneca PlcAdenocarcinoma of Lung; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
TQB-2868TQB-2868Phase 3 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupCarcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms
Details
Pembrolizumab/VibostolimabMK-7684APhase 3 ClinicalMerck & Co IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Hematologic Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
707 (3SBio)SSGJ707; SSGJ-707; 707; PF-08634404Phase 3 Clinical3sbio IncCarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Digestive System Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Diseases; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
IBI-363IBI-363Phase 3 ClinicalCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphoma; Melanoma; Mucosal Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
Details
Pembrolizumab biosimilar (biocad)BCD-201Phase 3 ClinicalBIOCAD JSCCarcinoma, Non-Small-Cell Lung; Melanoma; Skin Melanoma; Solid tumours
Details
INCA-33890INCA33890; INCA-33890Phase 3 ClinicalIncyte CorpColorectal Neoplasms; Ovarian Neoplasms; Solid tumours
Details
Nivolumab biosimilar(Amgen)ABP-206Phase 3 ClinicalAmgen IncMelanoma
Details
Pembrolizumab biosimilar (Qilu)QL2107; QL-2107Phase 3 ClinicalQilu Pharmaceutical Co LtdBile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Melanoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
PD-1 Inhibitor Therapy(Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University)Phase 3 ClinicalSun Yat-Sen Memorial Hospital Of Sun Yat-Sen UniversityCarcinoma, Hepatocellular; Rejection of liver transplantation; Squamous Cell Carcinoma of Head and Neck
Details
Nivolumab biosimilar (Biocad)BCD-263Phase 3 ClinicalBIOCAD JSCMelanoma; Skin Melanoma
Details
Pembrolizumab biosimilar (Shanghai Henlius Biotech Inc)HLX-17Phase 3 ClinicalCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Solid tumours
Details
SCTB-14SCTB-14; SCTB14Phase 3 ClinicalSinoCelltech LtdBile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
Pembrolizumab Biosimilar (Samsung Bioepis )SB27; SB-27Phase 3 ClinicalSamsung Bioepis Co LtdCarcinoma, Non-Small-Cell Lung
Details
Pembrolizumab biosimilar(R-Pharm)RPH-075Phase 3 ClinicalR-Pharm JscCarcinoma, Non-Small-Cell Lung; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck
Details
Pembrolizumab biosimilar (Laboratorio Elea Phoenix Sa)MB-12; MB12Phase 3 ClinicalLaboratorio Elea Phoenix SaCarcinoma, Non-Small-Cell Lung
Details
Pembrolizumab biosimilar (Amgen)ABP 234; ABP-234Phase 3 ClinicalAmgen IncCarcinoma, Non-Small-Cell Lung
Details
Pembrolizumab biosimilar (Celltrion)CT-P51Phase 3 ClinicalCelltrion IncCarcinoma, Non-Small-Cell Lung; Lung Neoplasms; Melanoma; Stomach Neoplasms
Details
Atigotatug/NivolumabBMS-986489Phase 3 ClinicalBristol-Myers Squibb CompanySmall Cell Lung Carcinoma
Details
Nivolumab Biosimilar (Mabxience Research)MB-11 (Mabxience Research); MB11 (Mabxience Research)Phase 3 ClinicalMabxience Research SLMelanoma
Details
RulonilimabF-520Phase 3 ClinicalShandong New Time Pharmaceutical Co LtdCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Central Nervous System Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Neoplasms; Solid tumours; Uterine Cervical Neoplasms
Details
JS-207JS-207Phase 3 ClinicalDotbio Pte Ltd, Shanghai Junshi Biosciences Co LtdCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms
Details
TebotelimabPD-1 X LAG-3; MGD-013Phase 3 ClinicalMacrogenics IncBiliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
Nurulimab/ProlgolimabBCD-217; BCD-145/BCD-100Phase 3 ClinicalBIOCAD JSCMelanoma; Skin Melanoma
Details
VolrustomigMEDI5752; MEDI-5752Phase 3 ClinicalMedimmune LlcBile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Mesothelioma; Papillomavirus Infections; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms
Details
GenolimzumabCBT-501; APL-501; APL501; GB226; GB-226Phase 3 ClinicalApollomics Inc, Apollomics Inc, Genor Biopharma Co LtdCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Microsatellite Instability; Mismatch Repair Deficient Cancer; Neoplasms, Unknown Primary; Sarcoma, Alveolar Soft Part; Solid tumours; Thymoma; Thymus Neoplasms; Uterine Cervical Neoplasms
Details
BAT-1308BAT-1308Phase 3 ClinicalBio-Thera Solutions LtdCarcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
NofazinlimabCS-1003Phase 3 ClinicalCstone PharmaceuticalsCarcinoma, Hepatocellular; Lymphoma; Neoplasms; Solid tumours
Details
IparomlimabQL1604; QL-1604; PSB-103Phase 3 ClinicalQilu Puget Sound Biotherapeutics CorpAdenocarcinoma; Carcinoma, Hepatocellular; Esophageal Neoplasms; Gallbladder Neoplasms; Liver Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms
Details
CetrelimabJNJ-63723283; JNJ-3283Phase 3 ClinicalJohnson & JohnsonCarcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Hepatitis B, Chronic; Hormone-Sensitive Prostate Neoplasms; Melanoma; Multiple Myeloma; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Urinary Bladder Neoplasms
Details
BudigalimabABBV-181Phase 3 ClinicalAbbvie IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; HIV Infections; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details

Resource download

  • Background
  • Product Features
  • Product List
  • Validation Data
  • Clinical Drug Information Table
  • Related Product Recommendations
  • Resource download